Recent developments include quarterly earnings calls, insider transactions, and investor fund selling impacting Alphatec's stock and operational outlook.

• Alphatec held its Q2 2026 earnings call, providing detailed operational and financial updates [N1].
• Q2 2026 earnings results lagged some expectations, with discussions highlighting challenges [N2][N3].
• Lisanti Capital sold $5.4 million worth of Alphatec shares amid company struggles reported in May 2026 [N4].
• A fund disclosed selling $18 million in Alphatec shares last quarter, coinciding with a 20% stock price decline after earnings [N5].
• Alphatec reported break-even earnings for Q1 2026, indicating a transition phase in profitability [N7][N6].
• The company continues to expand its surgeon user base and product portfolio to drive growth [N1].

Alphatec's focused spine surgery technology and integrated InformatiX platform position it as a leader in clinical innovation within its niche. Continued expansion of its surgeon user base and product portfolio could sustain revenue growth. Strategic investments in sales and marketing may enhance market penetration. The company's active capital management and liquidity provide operational flexibility to support growth initiatives.

The company faces risks from litigation, as indicated by increased litigation-related expenses and ongoing legal matters. Interest expense and debt-related costs have risen, reflecting increased borrowings and note redemptions, which may pressure financial performance. Investor selling activity and insider stock transactions have influenced stock volatility. Exposure to foreign currency risk may increase with international expansion. Execution risks include sustaining market share growth and managing operating expenses effectively.

Alphatec's moat derives from its exclusive focus on spine surgery technology, deep clinical expertise, and proprietary integration of surgical technologies via its InformatiX platform. This specialization supports industry-leading market share expansion and surgeon adoption. The company's comprehensive product portfolio and ongoing innovation efforts create barriers to entry for competitors. Additionally, its established sales network and relationships with surgeons and hospitals reinforce its market position.

• Litigation Risk: Alphatec has ongoing and settled litigation matters resulting in increased litigation-related expenses, which could materially affect future financial results.
• Financial Leverage and Interest Expense: The company has increased interest expense and loss on debt extinguishment due to additional borrowings and convertible notes redemption, impacting net income.
• Market and Investor Sentiment: Significant insider selling and fund selling have contributed to stock price volatility and may affect investor confidence.
• Foreign Currency Exposure: As international business grows, Alphatec faces foreign currency exchange risks that could impact financial results.
• Operational Execution: Sustaining revenue growth and managing operating expenses, including sales and marketing investments, are critical to maintaining market position.

• Alphatec Holdings, Inc. is a medical technology company focused exclusively on the design, development, and advancement of technology for surgical treatment of spine disorders, headquartered in Carlsbad, California.
• The company offers a comprehensive product portfolio addressing various spine pathologies, including spinal surgery implants such as pedicle screws, interbody devices, plates, tissue-based materials, and medical imaging equipment like EOS full-body and weight-bearing x-ray imaging devices.
• Alphatec markets and sells its products through a network of independent sales agents and direct sales representatives, targeting surgeons, hospitals, and surgical centers primarily in the U.S.
• The company has experienced approximately 35% compound annual revenue growth since 2018, driven by market share expansion and adoption of its technology.
• In March 2025, Alphatec issued $405 million principal amount of unsecured senior convertible notes due 2030 with a 0.75% interest rate, using proceeds for general corporate purposes and repurchasing prior notes.
• For the quarter ended September 30, 2026, Alphatec reported cash and cash equivalents of $79.9 million, current assets of $427.2 million, current liabilities of $180.8 million, resulting in a current ratio of 2.36 and a cash ratio of 0.44.
• The company reported a net loss of $5.5 million and basic and diluted EPS of -$0.03 for the quarter ended September 30, 2026.
• Revenue data from SEC filings shows $23.0 million for Q3 2018; more recent revenue figures are not disclosed in the provided excerpts.
• Operating expenses include research and development, sales, general and administrative expenses, litigation-related expenses, amortization of acquired intangible assets, transaction-related expenses, and restructuring expenses.
• Research and development expenses decreased by 6% in 2025 compared to 2024, while sales, general and administrative expenses increased by 11% in the same period, reflecting investments in sales and marketing.
• Litigation-related expenses increased significantly in 2025 due to a litigation settlement and ongoing matters.
• Interest expense and loss on debt extinguishment increased notably in 2025, related to additional borrowings and redemption of prior notes.
• Alphatec's liquidity and capital resources include cash, revolving credit facility, and cash from operations, with ongoing evaluation of capital needs for operations, R&D, sales expansion, and international growth.
• The company acknowledges exposure to foreign currency exchange risk as international business grows but currently has no material exposure outside the U.S.
• Recent news highlights include Q2 2026 earnings call transcripts and reports indicating earnings lagging estimates, insider buying and selling activity, and investor fund selling pressure impacting stock price.
• The company reported break-even earnings for Q1 2026 and has ongoing efforts to expand its surgeon user base and product portfolio.
• Alphatec's business model centers on clinical distinction and integration of technology through its InformatiX platform to improve spine surgery outcomes.
• The company has a history of strategic financing activities including convertible notes issuance and repurchases to manage capital structure.